Search Results for: covid-19
Articles
IMMUNE ACTIVATORS - Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies March 1, 2021
Siddhartha De, PhD, and Peter Vanderslice, PhD, present their research on the use of proprietary, orally available compounds that can activate the immune system to enhance the effectiveness of vaccines as well as immuno-oncology therapies for cancer, especially in patient populations that are most vulnerable to disease.
Mateon Therapeutics & Windlas Biotech Launch India's First Combined Lung Therapy & AI Telemedicine Solution February 24, 2021
Mateon Therapeutics, Inc. and Windlas Biotech Pvt. Ltd. recently announced the launch in India of PulmoHeal, a first-of-its-kind integrated, consumer-centric...Halberd Collaborates With GreenBioAZ for the Development of Its Patent Pending Radio Frequency Technology February 24, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent-pending Radio Frequency (RF) extracorporeal treatment to eliminate...Intra-Cellular Therapies Applies for FDA Approval of Bipolar Depression Treatment February 24, 2021
Intra-Cellular Therapies, Inc. recently announced it has submitted supplemental New Drug Applications (sNDAs) to the US FDA for two indications...Halberd Collaborates With GreenBioAZ for the Development of Radio Frequency Technology to Eliminate Disease Pathogens February 17, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate….
Enlivex Announces Issuance of New US Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis & GvHD Using Allocetra Immunotherapy February 17, 2021
Enlivex Therapeutics Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,927,343 covering Allocetra, the...OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics February 11, 2021
OliX Pharmaceuticals, Inc. recently announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of...Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis February 4, 2021
Biogen Inc. recently announced the US FDA has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of….
Relief Therapeutics & Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration & License Agreement January 28, 2021
Relief Therapeutics Holding AG and Acer Therapeutics Inc. recently announced the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license….
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study January 28, 2021
DURECT Corporation recently announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the...Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial January 21, 2021
Caladrius Biosciences, Inc. recently announced it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as...SPECIAL FEATURE - Outsourcing Analytical Testing: Innovative Drugs Spike Demand for Advanced Analysis January 14, 2021
Contributor Cindy H. Dubin asked some of the key analytical testing providers to describe their offerings in several key areas and what advanced analytical testing techniques they can offer to pharma clients.
EXECUTIVE INTERVIEW - BiologIC Technologies: The Future Microsoft for the Biorevolution January 13, 2021
Richard Vellacott, CEO of BiologIC Technologies, discusses his company’s unique technology and its applications in the future of medicine and wider fields of synthetic biology.
EXECUTIVE INTERVIEW - Fortress Biotech, Inc.: Looking for the Muffin Tops January 13, 2021
Lindsay A. Rosenwald, MD, Chairman, President, and CEO of Fortress Biotech, discusses how his medical and financial knowledge come together to find successful drug candidates, the company’s partnership model, and the inefficiencies he sees in the biotech industry.
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion January 7, 2021
Catalyst Pharmaceuticals, Inc. recently announced an expansion in its strategic priorities related to portfolio planning and research and development. Catalyst...EyePoint Pharmaceuticals Announces $15.7-Million Equity Investment January 4, 2021
EyePoint Pharmaceuticals, Inc. recently announced Ocumension Therapeutics has made a $15.7-million equity investment in EyePoint. Under the terms of the...Syneos Health & ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence & AI to Advance Oncology Research December 9, 2020
Syneos Health and ConcertAI recently announced a strategic collaboration to accelerate and streamline the implementation of novel oncology clinical trial research and study designs…..
Biogen & Sage Therapeutics Announce Global Development & Commercialization Collaboration December 2, 2020
Biogen Inc. and Sage Therapeutics, Inc. recently announced they have executed a global collaboration and license agreement to jointly develop...Samsung Biologics Breaks Ground on Super Plant, the World’s Largest & Most Innovative Bio-Manufacturing Facility December 2, 2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant,” the new, multi-story...Gene Therapy Market to Surpass $6.21 Billion Globally, by 2027 at 13.4% CAGR December 2, 2020
Allied Market Research published a report, titled Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type...
